The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Study of oral clofarabine plus low-dose cytarabine in previously treated AML and high-risk MDS patients at least age 60.
K. M. Smith
No relevant relationships to disclose
E. Estey
No relevant relationships to disclose
J. M. Pagel
No relevant relationships to disclose